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oes Renal Clearance
iffer Between the
-Type Natriuretic Peptides
BNP Versus NT-proBNP)?*
uetonia C. Palmer, MB CHB, FRACP,
. Mark Richards, MD, PHD, DSC, FRCP, FRACP
hristchurch, New Zealand
lasma B-type natriuretic peptides (BNP and the amino-
erminal portion of proBNP [NT-proBNP]), both reflect-
ng myocardial wall tension, are established biomarkers for
iagnosis, risk stratification, and prognosis across popula-
ions with or at risk of cardiovascular disease. Observational
tudies consistently show that elevated circulating B-type
atriuretic peptide levels correlate with declining kidney
unction. Further, plasma NT-proBNP levels are elevated
ore than BNP for a similar decrement in glomerular
ltration rate. The widely reported assumption is that
T-proBNP—and less so BNP—accumulate in kidney
isease because of impaired renal clearance.
See page 884
The issue of relative production and clearance of a
iomarker is an important one; plasma B-type natriuretic
eptides potentially lose clinical utility as determinants of
yocardial stress if kidney function plays a progressively
ore important role (relative to cardiac function) in deter-
ining plasma peptide levels as kidney function declines.
ith the rapidly increasing prevalence of kidney disease in
uman populations (1) and the guideline acceptance of
-type natriuretic peptide levels as diagnostic tools in heart
ailure, the processes of B-type natriuretic peptide clearance
re pivotal to the interpretation of plasma levels as measures
f myocardial function.
Observational data linking natriuretic peptides and kid-
ey function are at best hypothesis forming; the mecha-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, University of Otago Christchurch,
hristchurch, New Zealand. Dr. Richards has had consultancy connections with
oth Biosite, which markets a B-type natriuretic peptide assay, and Roche Diagnos-N
ics, which markets an amino-terminal pro–B-type natriuretic peptide assay. Dr.
ichards has received honoraria and research grant support from Roche Diagnostics.isms for elevated B-type natriuretic peptide levels in people
ith renal dysfunction remain unclear. The pivotal question
emains unresolved: does kidney function determine peptide
evels through clearance or confound peptide levels through
ts powerful association with prevalent cardiac disease,
hich causes elevated cardiac production of BNP and NT-
roBNP? Further, although known processes (receptor-
ediated clearance and enzymatic degradation) eliminate
NP, mechanisms for NT-proBNP clearance remain un-
nown. In contrast to BNP (2), the proportional roles of
enal and extra-renal tissue in removal of circulating NT-
roBNP remain both unmeasured and uncertain.
In this issue of the Journal, van Kimmenade et al. (3)
irectly measure and compare BNP and NT-proBNP levels
cross the renal circulation of 165 hypertensive patients
ndergoing angiography for suspected renal artery stenosis.
ost patients had an estimated glomerular filtration rate
eGFR) above 30 ml/min/1.73 m2. As expected, plasma
mmunoreactive BNP and NT-proBNP and the plasma
atio of NT-proBNP to BNP inversely correlated with
GFR. Renal fractional extractions of BNP and NT-
roBNP were 21% to 22% and 16% to 18%, respectively.
hereas eGFR predicted the fractional extraction of both
NP and NT-proBNP, the ratio for renal extraction of
T-proBNP to BNP (FENT-proBNP/BNP) was unrelated to
GFR, suggesting that BNP and NT-proBNP are equally
ependent on renal function for elimination. Multivariable
nalysis, incorporating clinical (age, body mass, blood pres-
ure, hematocrit), renal (relative renal plasma flow, peptide
ractional extraction, and eGFR), and cardiac (left ventric-
lar ejection fraction, left ventricular mass index, and E/A
atio) variables, identified eGFR, renal plasma flow, and left
entricular mass index but not fractional peptide extraction
s independent predictors of circulating B-type peptide
evels.
Since the introduction of B-type peptides into clinical
ractice, confusion has existed about their utility in the
ontext of renal dysfunction. Circulating BNP is reportedly
ess reliant on kidney function for removal and therefore a
ore robust clinical biomarker in kidney disease. Propaga-
ion of this belief, often firmly held, ensued after some
bservational studies showed a closer inverse relationship
etween plasma NT-proBNP and creatinine clearance. In
act, similar or identical correlations for both NT-proBNP
nd BNP with eGFR are observed when the peptides are
ssayed together in patients with coronary artery disease or
ndifferentiated dyspnea, although such analyses are limited
y the small proportion of patients with eGFR 30
l/min/1.73 m2 (4–6). Further, clearance of BNP is
ifferent from NT-proBNP; the well-defined mechanisms
or BNP elimination by natriuretic peptide receptor C and
eutral endopeptidase contrast with the unknown processes
or NT-proBNP degradation. The absence of known elim-
nation pathways for NT-proBNP and evidence for urinary
T-proBNP immunoreactivity have prompted speculation
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BNP Versus NT-proBNP March 10, 2009:891–2f a more important role for renal clearance of NT-proBNP
y glomerular filtration compared with other processes of
egradation.
The current report echoes 3 similarly conducted smaller
tudies (20 patients) all showing concordant renal frac-
ional extraction for BNP and NT-proBNP (7–9). The
trength of the new analysis is a sample size large enough to
ustain regression analyses showing that renal fractional
xtraction does not independently predict circulating levels
or either peptide.
Although data showing equal dependence on eGFR for
limination of both peptides are novel, the mechanisms for
elatively higher circulating NT-proBNP levels in renal
mpairment remain unclear. Further, it would have been
nteresting to observe whether renal extractions of NT-
roBNP and BNP within an individual were statistically
imilar (or different) when directly compared.
The ratio of circulating NT-proBNP to BNP immuno-
eactivity increases as kidney function declines without a
orresponding elevation in fractional renal NT-proBNP
xtraction, suggesting a saturable clearance mechanism for
T-proBNP that is independent of glomerular filtration or
ugmented clearance of BNP with lower eGFR. Lack of
orrelation between urinary NT-proBNP immunoreactivity
nd contemporaneous plasma NT-proBNP levels and
GFR (10) supports the possibility that NT-proBNP clear-
nce is at least in part independent of eGFR. In this regard,
t would be of interest to know whether other tissues
egrade immunoreactive NT-proBNP; evidence for extrac-
ion across other sites in the human circulation would
rovide indirect support for additional processes of NT-
roBNP degradation. Although renal fractional extraction
f both BNP and NT-proBNP is lower with impaired
FR, such a correlation does not prove causation—that
lomerular filtration is the major mechanism through which
-type natriuretic peptides inversely associate with renal
unction. Indeed, the predictive power of renal peptide
xtraction is lost when incorporated into a multivariable
odel alongside eGFR and cardiac characteristics including
oth left ventricular ejection fraction and mass index, hence
etaining the possibility that higher peptide levels in kidney
isease are a true positive finding. In other words, higher
-type natriuretic peptide levels in chronic kidney disease
ay signal clinically important cardiac pathology. Preserva-
ion of prognostic information given by BNP and NT-
roBNP beyond that provided by conventional risk factors
ncluding cardiac structure and function, even in patients
ith markedly impaired kidney function, supports the
oncept that peptide levels remain a powerful reflection of
ardiac status in kidney disease. Measuring cardiac secretion
f both peptides in patients with a range of eGFRs would
K
rrovide valuable information to support or refute this
ypothesis.
That NT-proBNP and BNP are equally dependent on
enal function for clearance is an advance for clinical
pplication of these biomarkers. As van Kimmenade et al.
3) suggest, these analyses need to be conducted in patients
n whom the B-type natriuretic peptides are most widely
sed in real life—those with heart failure with and without
everely impaired eGFR (30 ml/min/1.73 m2). Further,
he assay used for each peptide in the current study only
easures degradation of peptide epitopes detected by the
ntibodies for that particular assay. Clearance of both BNP
nd NT-proBNP may have been different using assays with
iffering antigen specificities, which also might provide
nsight into the processes of degradation for NT-proBNP.
eprint requests and correspondence: Dr. A. Mark Richards,
epartment of Medicine, University of Otago Christchurch, P.O.
ox 4345, Christchurch 8140, NewZealand. E-mail: mark.richards@
dhb.govt.nz.
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